ERBB2 and neoplasm: A bispecific antibody binding the Vγ9 chain and HER2 tumor antigen enhanced Vγ9Vδ2 T cell in vitro and in vivo killing of pancreatic adenocarcinomas, with superior in vitro killing compared to pAg stimulated γδ T cells alone or with a CD3/HER2 bispecific antibody [120].